Shanghai Sekangte Pharmaceutical

Shanghai Sekangte Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative peptide drugs for metabolic diseases. The company's research focuses on multi-target agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors to treat obesity, type 2 diabetes, and MASH. Its lead asset, SKT01, is a long-acting triple receptor agonist currently undergoing Phase 1 clinical evaluation in China. Sekangte aims to leverage its proprietary peptide engineering platform to create differentiated therapies with superior weight loss and glycemic control profiles. The company was founded in 2021 by industry veterans with extensive experience in metabolic drug development.